Following the publication of the first two volumes of our landmark, 1000-page analytical report on the emerging longevity industry in early 2018, titled Longevity Industry Landscape Overview 2017, Volume 1: The Science of Longevity and Volume 2: The Business of Longevity, we plan on continuing full steam ahead with several follow-up volumes, including:Volume III: Special Case Studies This volume will profile distinct subtopics and research themes within the broader geroscience industry and research landscape, e.g. biomarkers of aging, cell therapies, gene therapies. Volume IV: Novel Financial Systems This volume will focus on the economics of aging and how the emerging longevity industry and geroscience research landscape could help to reshape the global economy in the decades to come. Volume V: Regional Case StudiesThis volume will give an in-depth overview of the longevity industry and geroscience research landscape in specific geographic regions, including the UK, Japan and Italy
In 2017 we forged a partnership with the Oxford University Scientific Society (OUSS) to jointly engage in and support ageing research-oriented public outreach and education activities within Oxford University, including the release of the Longevity Podcast by BGRF Director of Public Outreach and Education and OUSS President Jack Stefaniak, which willfeature analysis of the latest research in geroscience and interviews with the field’s key thought leaders. Throughout 2018 we plan on continuing our podcast and expanding our activities to include several conferences on the subject of longevity at Oxford University. Part of the funds we raise for 2018 will be earmarked for these activities.
Throughout 2017 we published several seminal papers in top-tier scientific journals including Aging, Oncotarget, Aging Cell, Cell Cycle, Human Gene Therapy, Molecular Pharmaceutics, Clinical Cancer Research and more. Some of the funds we raise will be earmarked for the scientists and researchers working on studies and papers we are preparing to publish throughout the coming year.
In 2017 we submitted aproposal to the 11th round of revision for the World Health Organization’s International Classification of Diseases system (the main disease classification system used by the majority of developed nations) to classify ageing as a disease based on existing clinical evidence of the causal mechanisms underlying aging and the effectiveness of various interventions in modulating those causal mechanisms. The classification of aging as a disease is a necessary prerequisite for the clinical evaluation and approval of any future healthspan extending therapy, and the results of our proposal are still being considered by the WHO.
In 2017 we launched the beta version of our decentralized longevity
knowledge, analytics, database and networking platform, Longevity.International. Throughout 2018 we plan on continuing development of the platform and significantly enhancing its longevity industry databases (consisting of filterable databases on key longevity companies, investors, scientists, research labs, non-profit organizations, conferences, scientific journals and books) and implementing a ranking system whereby different stakeholders on the platform are ranked according to their impact upon the industry, with the ultimate aim of providing a framework for conducting scientific and technical due diligence on new longevity startups and ventures, as well as emerging research trends within the geroscience field.
In 2017 we successfully raised funds for the development and validation of AI-powered photographic biomarkers of aging in mice via deeplearningalgorithms that can predict a subject’s biological age via deep learning-based analysis. We consider the development of accurate and actionable biomarkers of aging to be one of the most important objectives within ageing research, because biomarkers of age are a prerequisite for testing the effectiveness of any healthspan-extending interventions. Throughout 2018 we plan on fully developing the mobile app associated with this project, validating its effectiveness and publishing the results, and then moving on to validation in human subjects.